GLP-1 Drugs May Lower Cardiovascular Risk

What Did the New TAVI Analysis Find About GLP-1 Drugs?

According to coverage from TCTMD, a recent analysis presented to the interventional cardiology community suggests that patients undergoing transcatheter aortic valve implantation (TAVI) who were also taking a GLP-1 receptor agonist had favorable cardiovascular outcomes compared with similar patients not on these drugs. The signal was strongest in patients with type 2 diabetes or obesity, two populations who are increasingly common among TAVI candidates as average procedural age drops and indications expand.

The analysis adds to a rapidly growing body of evidence positioning GLP-1 agonists as cardiometabolic, not just glucose-lowering, drugs. While the data are observational and require confirmation in randomized trials, they are consistent with established findings from large outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and SELECT (semaglutide in obesity without diabetes), all of which demonstrated reductions in major adverse cardiovascular events.

How Might GLP-1 Receptor Agonists Protect the Heart After Valve Replacement?

GLP-1 receptor agonists work by mimicking the gut hormone glucagon-like peptide-1, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Beyond glycemia, the drugs lower body weight, blood pressure, and markers of inflammation — all relevant in patients with severe aortic stenosis, where comorbid metabolic disease is common.

For TAVI patients specifically, post-procedural risk is shaped by atherosclerotic disease, heart failure, atrial fibrillation, and renal dysfunction. By improving the underlying metabolic milieu and possibly exerting direct effects on endothelial function and myocardial remodeling, GLP-1 therapy could plausibly reduce events such as myocardial infarction, stroke, and heart failure hospitalization in the months and years after valve replacement.

Should Cardiologists Start Prescribing GLP-1 Drugs Around TAVI?

The current data come from observational analyses, which can be confounded by indication bias: patients who are prescribed GLP-1 agonists may differ in important ways from those who are not. Established guidelines from the American Diabetes Association and the European Society of Cardiology already recommend GLP-1 receptor agonists for patients with type 2 diabetes and established or high cardiovascular risk, and increasingly for obesity with cardiovascular comorbidity following the SELECT trial.

For now, the appropriate clinical takeaway is that eligible TAVI candidates with diabetes or obesity should be evaluated for guideline-directed GLP-1 therapy as part of comprehensive cardiometabolic care. Whether GLP-1 drugs should be initiated specifically because of an upcoming TAVI procedure remains a research question that randomized trials will need to answer.